Literature DB >> 24111754

Midkine as a regulator of B cell survival in health and disease.

Sivan Cohen1, Idit Shachar.   

Abstract

UNLABELLED: In healthy individuals, the pool of peripheral lymphocytes is constant in size. The control of lymphoid homeostasis is the result of a very fine balance between lymphocyte production, survival and proliferation. Survival factors have been shown to play a critical role in maintaining the correct size of lymphocyte populations. Midkine, a heparin-binding cytokine was recently shown to be involved in cell proliferation, differentiation and apoptosis in various cell types including normal and malignant B cells. This review focuses on the role of midkine in the regulation of peripheral B cell survival in health and disease. LINKED ARTICLES: This article is part of a themed section on Midkine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-4.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  B cells; BAFF; BCR; CD74; MIF; invariant chain; survival

Mesh:

Substances:

Year:  2014        PMID: 24111754      PMCID: PMC3925027          DOI: 10.1111/bph.12419

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  88 in total

1.  LDL receptor-related protein as a component of the midkine receptor.

Authors:  H Muramatsu; K Zou; N Sakaguchi; S Ikematsu; S Sakuma; T Muramatsu
Journal:  Biochem Biophys Res Commun       Date:  2000-04-21       Impact factor: 3.575

2.  Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells.

Authors:  Weihua Wan; Mark S Albom; Lihui Lu; Matthew R Quail; Nadine C Becknell; Linda R Weinberg; Dandu R Reddy; Beverly P Holskin; Thelma S Angeles; Ted L Underiner; Sheryl L Meyer; Robert L Hudkins; Bruce D Dorsey; Mark A Ator; Bruce A Ruggeri; Mangeng Cheng
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

3.  Invariant chain induces B cell maturation by activating a TAF(II)105-NF-kappaB-dependent transcription program.

Authors:  D Matza; O Wolstein; R Dikstein; I Shachar
Journal:  J Biol Chem       Date:  2001-05-22       Impact factor: 5.157

Review 4.  The role of APRIL and BAFF in lymphocyte activation.

Authors:  Pascal Schneider
Journal:  Curr Opin Immunol       Date:  2005-06       Impact factor: 7.486

5.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

6.  Synthesis and release of B-lymphocyte stimulator from myeloid cells.

Authors:  B Nardelli; O Belvedere; V Roschke; P A Moore; H S Olsen; T S Migone; S Sosnovtseva; J A Carrell; P Feng; J G Giri; D M Hilbert
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

7.  TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS.

Authors:  J A Gross; S R Dillon; S Mudri; J Johnston; A Littau; R Roque; M Rixon; O Schou; K P Foley; H Haugen; S McMillen; K Waggie; R W Schreckhise; K Shoemaker; T Vu; M Moore; A Grossman; C H Clegg
Journal:  Immunity       Date:  2001-08       Impact factor: 31.745

8.  An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway.

Authors:  B Schiemann; J L Gommerman; K Vora; T G Cachero; S Shulga-Morskaya; M Dobles; E Frew; M L Scott
Journal:  Science       Date:  2001-08-16       Impact factor: 47.728

9.  Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response.

Authors:  R K Do; E Hatada; H Lee; M R Tourigny; D Hilbert; S Chen-Kiang
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

10.  Serum midkine levels are increased in patients with various types of carcinomas.

Authors:  S Ikematsu; A Yano; K Aridome; M Kikuchi; H Kumai; H Nagano; K Okamoto; M Oda; S Sakuma; T Aikou; H Muramatsu; K Kadomatsu; T Muramatsu
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

View more
  5 in total

1.  Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment.

Authors:  Catherine Gutierrez; Aziz M Al'Khafaji; Eric Brenner; Kaitlyn E Johnson; Satyen H Gohil; Ziao Lin; Binyamin A Knisbacher; Russell E Durrett; Shuqiang Li; Salma Parvin; Anat Biran; Wandi Zhang; Laura Rassenti; Thomas J Kipps; Kenneth J Livak; Donna Neuberg; Anthony Letai; Gad Getz; Catherine J Wu; Amy Brock
Journal:  Nat Cancer       Date:  2021-07-12

2.  Midkine: an emerging target of drug development for treatment of multiple diseases.

Authors:  Takashi Muramatsu; Kenji Kadomatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 3.  Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.

Authors:  Panagiota S Filippou; George S Karagiannis; Anastasia Constantinidou
Journal:  Oncogene       Date:  2019-12-04       Impact factor: 9.867

4.  Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis.

Authors:  Lisa M Rice; Julio C Mantero; Eric A Stratton; Rod Warburton; Kari Roberts; Nicholas Hill; Robert W Simms; Robyn Domsic; Harrison W Farber; Robert Layfatis
Journal:  Arthritis Res Ther       Date:  2018-08-16       Impact factor: 5.156

5.  Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma.

Authors:  Petra Schneiderova; Tomas Pika; Petr Gajdos; Regina Fillerova; Pavel Kromer; Milos Kudelka; Jiri Minarik; Tomas Papajik; Vlastimil Scudla; Eva Kriegova
Journal:  Oncotarget       Date:  2016-08-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.